Enzon Pharmaceuticals, Inc. (ENZN)
OTCMKTS
· Delayed Price · Currency is USD
0.1098
+0.0060 (5.78%)
Mar 31, 2025, 3:26 PM EST
Enzon Pharmaceuticals Revenue
In the year 2024, Enzon Pharmaceuticals had annual revenue of $26.00K.
Revenue
26.00K
Revenue Growth
n/a
P/S Ratio
293.91
Revenue / Employee
26.00K
Employees
1
Market Cap
7.63M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.00K | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 26.00K | -675.00K | -96.29% |
Dec 31, 2021 | 701.00K | 649.00K | 1,248.08% |
Dec 31, 2020 | 52.00K | -155.00K | -74.88% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
Enzon Pharmaceuticals News
- 4 years ago - Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO - GlobeNewsWire
- 4 years ago - Enzon Pharmaceuticals Announces Results of Rights Offering - GlobeNewsWire
- 4 years ago - Enzon Pharmaceuticals Announces Key Dates for Rights Offering - GlobeNewsWire
- 4 years ago - Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value - GlobeNewsWire
- 5 years ago - Bullish On Enzon And Sesen From Different Perspectives - Seeking Alpha
- 6 years ago - Enzon Pharmaceuticals - Heads Equals Royalties, Tails Equals Cash - Seeking Alpha